Literature DB >> 17537137

Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus.

Joerg Albrecht1, Victoria P Werth.   

Abstract

Skin involvement is a frequent presenting manifestation of systemic lupus erythematosus (SLE). Cutaneous lupus erythematosus (CLE), frequently occurring without SLE, may be even more common than SLE. Until recently, clinical instruments to measure skin involvement in CLE did not exist, hampering clinical research in this field. In this paper the present authors describe outcome instruments for SLE and outline the considerations underlying the design and validation of an outcome instrument for CLE, the cutaneous lupus disease area and severity index. These studies serve as a model for development and validation of standardized instruments that can be applied to other cutaneous diseases, particularly autoimmune diseases, in order to facilitate epidemiologic studies and clinical trials.

Entities:  

Mesh:

Year:  2007        PMID: 17537137     DOI: 10.1111/j.1529-8019.2007.00117.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  19 in total

1.  Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.

Authors:  Rachel S Klein; Pamela A Morganroth; Victoria P Werth
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

2.  Prevalence of self-report photosensitivity in cutaneous lupus erythematosus.

Authors:  Kristen Foering; Renato Goreshi; Rachel Klein; Joyce Okawa; Mathew Rose; Andrew Cucchiara; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-07-13       Impact factor: 11.527

Review 3.  Treatment of cutaneous lupus.

Authors:  Aileen Y Chang; Victoria P Werth
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

4.  Quality of life in cutaneous lupus erythematosus.

Authors:  Rachel Klein; Siamak Moghadam-Kia; Lynne Taylor; Christopher Coley; Joyce Okawa; Jonathan LoMonico; Mary-Margaret Chren; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-03-12       Impact factor: 11.527

Review 5.  Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation.

Authors:  Thrasivoulos George Tzellos; Dimitrios Kouvelas
Journal:  Eur J Clin Pharmacol       Date:  2007-12-20       Impact factor: 2.953

6.  Characterization of clinical photosensitivity in cutaneous lupus erythematosus.

Authors:  Kristen Foering; Aileen Y Chang; Evan W Piette; Andrew Cucchiara; Joyce Okawa; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2013-05-03       Impact factor: 11.527

7.  Interventions for cutaneous disease in systemic lupus erythematosus.

Authors:  Cora W Hannon; Collette McCourt; Hermenio C Lima; Suephy Chen; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2021-03-09

8.  Cutaneous manifestations of systemic lupus erythematosus.

Authors:  Luís Uva; Diana Miguel; Catarina Pinheiro; João Pedro Freitas; Manuel Marques Gomes; Paulo Filipe
Journal:  Autoimmune Dis       Date:  2012-07-25

Review 9.  Development of outcome measures for autoimmune dermatoses.

Authors:  Elizabeth Gaines; Victoria P Werth
Journal:  Arch Dermatol Res       Date:  2007-11-06       Impact factor: 3.017

10.  Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study.

Authors:  Christa Ky; Brian Swasdibutra; Shaadi Khademi; Sheetal Desai; Vivian Laquer; Sergei A Grando
Journal:  Dermatol Reports       Date:  2015-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.